| Members |
associationTargetComponent |
| (Anti-D (rhesus) globulin) or (administration of) |
Administration of human anti-D immunoglobulin |
| (Anti-D (rhesus) globulin) or (therapy) |
Administration of human anti-D immunoglobulin |
| (Anti-D (rhesus) globulin) or (therapy) |
Administration of human anti-D immunoglobulin |
| (Carcinoma in situ cervix uteri) or (cerv intraepith neoplasia) or (cervix Ca in situ) |
Carcinoma in situ of uterine cervix |
| (GIT disorders NOS) or (kraurosis of anus) or (proctitis) or (rectal irritation) or (stercoral ulcer) |
Lichen sclerosus of anus |
| (Labour problem factors) or (problems affecting labour NOS) |
Disorder of labour / delivery |
| (Labour problem factors) or (problems affecting labour NOS) |
Disorder of labour / delivery |
| (Lactation problems) or (breast/lactation problems NOS) |
Disorder of lactation |
| (Lymphatic tissue carcinoma) or (lymphoma) |
Malignant lymphoma |
| (Mechanical complication of cardiac device) or (device problems) or (problems with prostheses) |
Mechanical complication of cardiovascular device |
| (Mechanical complication of cardiac device) or (device problems) or (problems with prostheses) |
Mechanical complication of cardiovascular device |
| (Mechanical complication of cardiac device, implant and graft) or (leakage due to cardiac device) |
Mechanical complication of cardiovascular device |
| (Monster) or (monster NOS) |
Congenital anomaly |
| (Monster) or (monster NOS) |
Congenital anomaly |
| (Post-operative problem NOS) or (postcardiotomy syndrome) |
Post-pericardiotomy syndrome |
| (Post-operative problem NOS) or (postcardiotomy syndrome) |
Post-pericardiotomy syndrome |
| (Recurrent aphthous ulceration) or (recurrent mouth ulcers) |
Recurrent ulcer of mouth |
| (Sprains and strains NOS) or (sprain: [joint NOS] or [ligament NOS] or [muscle NOS] or [rectus sprain] or [tendon NOS]) or (tendon rupture NOS) |
Strain of rectus abdominus muscle |
| 11-Deoxy, 17-hydroxycorticosterone |
11-deoxycortisol |
| 11-Oxy fraction of 17-KS |
11-oxy-17-ketosteroid |
| 11-Oxycorticosterone |
11-oxycorticosteroid |
| 12p partial monosomy syndrome |
Deletion of part of short arm of chromosome 12 |
| 15q partial monosomy syndrome |
Partial deletion of long arm of chromosome 15 |
| 15q partial trisomy syndrome |
Partial duplication of long arm of chromosome 15 |
| 16p partial trisomy syndrome |
Duplication of part of short arm of chromosome 16 |
| 16q partial monosomy syndrome |
Partial deletion of long arm of chromosome 16 |
| 16q partial trisomy syndrome |
Duplication of part of long arm of chromosome 16 |
| 17-Hydroxycorticosteroid |
17-hydroxycorticosteroid |
| 18-Hydroxycorticosterone dehydrogenase deficiency |
Corticosterone 18-monooxygenase deficiency |
| 2,3-Diaminopropionate oxalyltransferase |
2,3-diaminopropionate N-oxalyltransferase |
| 2,3,5-Trichlorophenoxyacetic acid |
2,4,5-trichlorophenoxyacetic acid |
| 2,5-Diokovalerate dehydrogenase |
2,5-dioxovalerate dehydrogenase |
| 2-Butanone |
Methyl ethyl ketone |
| 2-Nitro-1,1-bis(p-chlorophenyl) butane |
1,1-bis(4-chlorophenyl)-2-nitrobutane |
| 3% Acetic acid |
Acetic acid |
| 3,4,5,6-tetrabromo-ortho-cresol 1% + zinc undecenoate 5% + undecenoic acid 1% + zinc oxide 5% dusting powder |
Unknown Cell Type 2 |
| 3,4,5,6-tetrabromo-ortho-cresol 1% + zinc undecenoate 5% + undecenoic acid 1% + zinc oxide 5% dusting powder, 375 g |
Unknown Cell Type 2 |
| 3,4,5,6-tetrabromo-ortho-cresol 1% + zinc undecenoate 5% + undecenoic acid 1% + zinc oxide 5% dusting powder, 50 g |
Unknown Cell Type 2 |
| 3,4,5,6-tetrabromo-ortho-cresol 10 mg / 1 g + undecenoic acid 10 mg / 1 g + zinc oxide 50 mg / 1 g + zinc undecenoate 50 mg / 1 g dusting powder (medicinal product unit of use) |
Unknown Cell Type 2 |
| 3,4,5,6-tetrabromo-ortho-cresol 10 mg / 1 g + undecenoic acid 10 mg / 1 g + zinc oxide 50 mg / 1 g + zinc undecenoate 50 mg / 1 g dusting powder, 375 g (medicinal product pack) |
Unknown Cell Type 2 |
| 3,4,5,6-tetrabromo-ortho-cresol 10 mg / 1 g + undecenoic acid 10 mg / 1 g + zinc oxide 50 mg / 1 g + zinc undecenoate 50 mg / 1 g dusting powder, 50 g (medicinal product pack) |
Unknown Cell Type 2 |
| 3TC (lamivudine 10 mg / 1 mL) oral liquid solution, 1 mL measure (trade product unit of use) |
Unknown Cell Type 2 |
| 3TC (lamivudine 10 mg / 1 mL) oral liquid solution, 240 mL (trade product pack) |
Unknown Cell Type 2 |
| 3TC (lamivudine 10 mg / 1 mL) oral liquid solution, 240 mL, bottle (containered trade product pack) |
Unknown Cell Type 2 |
| 3TC (lamivudine 150 mg) film-coated tablet (trade product unit of use) |
Unknown Cell Type 2 |
| 3TC (lamivudine 150 mg) film-coated tablet, 60 tablets (trade product pack) |
Unknown Cell Type 2 |
| 3TC (lamivudine 150 mg) film-coated tablet, 60 tablets, bottle (containered trade product pack) |
Unknown Cell Type 2 |
| 3TC (lamivudine 300 mg) film-coated tablet (trade product unit of use) |
Unknown Cell Type 2 |
| 3TC (lamivudine 300 mg) film-coated tablet, 30 tablets (trade product pack) |
Unknown Cell Type 2 |
| 3TC (lamivudine 300 mg) film-coated tablet, 30 tablets, bottle (containered trade product pack) |
Unknown Cell Type 2 |
| 3TC 10 mg/mL oral liquid solution |
Unknown Cell Type 2 |
| 3TC 10 mg/mL oral liquid solution, 240 mL |
Unknown Cell Type 2 |
| 3TC 10 mg/mL oral liquid solution, 240 mL, bottle |
Unknown Cell Type 2 |
| 3TC 150 mg film-coated tablet |
Unknown Cell Type 2 |
| 3TC 150 mg film-coated tablet, 60 |
Unknown Cell Type 2 |
| 3TC 150 mg film-coated tablet, 60, bottle |
Unknown Cell Type 2 |
| 3TC 300 mg film-coated tablet |
Unknown Cell Type 2 |
| 3TC 300 mg film-coated tablet, 30 |
Unknown Cell Type 2 |
| 3TC 300 mg film-coated tablet, 30, bottle |
Unknown Cell Type 2 |
| 46, XX true hermaphrodite |
46,XX ovotesticular disorder of sex development |
| 5% Acetic acid |
Acetic acid |
| 6-Iodomethylnorcholesterol[131I] 8-30MBq/mL injection |
Norcholestenol iodomethyl (131-I) only product in parenteral dose form |
| 6-Iodomethylnorcholesterol[131I] 8-30MBq/mL powder for injection solution vial |
Norcholestenol iodomethyl (131-I) only product in parenteral dose form |
| 6-Iodomethylnorcholesterol[131I]37MBq/mL injection |
Norcholestenol iodomethyl (131-I) only product in parenteral dose form |
| 6-ketoprostaglandin F1 |
6-ketoprostaglandin F1 alpha |
| 6-minute walk test |
6 minute walk test distance |
| influenza virus quadrivalent vaccine 2015 injection, syringe |
influenza quadrivalent adult vaccine 2015 injection, 0.5 mL syringe |
| influenza virus quadrivalent vaccine 2015 injection, 10 x 0.5 mL syringes |
influenza quadrivalent adult vaccine 2015 injection, 10 x 0.5 mL syringes |
| A/Michigan/45/2015 (H1N1)pdm09-like virus 60 microgram + A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus 60 microgram + B/Phuket/3073/2013-like virus 60 microgram injection, 0.5 mL syringe (medicinal product unit of use) |
influenza trivalent geriatric vaccine 2018 injection, 0.5 mL syringe |
| influenza trivalent geriatric vaccine 2018 injection, 10 x 0.5 mL syringes |
influenza trivalent geriatric vaccine 2018 injection, 10 x 0.5 mL syringes |
| influenza trivalent geriatric vaccine 2018 injection, 5 x 0.5 mL syringes |
influenza trivalent geriatric vaccine 2018 injection, 5 x 0.5 mL syringes |
| ABO blood group antibody system |
ABO blood group system |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 0.5 mL syringe (trade product unit of use) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 0.5 mL vial (trade product unit of use) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 1 x 0.5 mL syringe (containered trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 1 x 0.5 mL syringe (trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 1 x 0.5 mL vial (containered trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 1 x 0.5 mL vial (trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 5 x 0.5 mL syringes (containered trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 5 x 0.5 mL syringes (trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 5 x 0.5 mL vials (containered trade product pack) |
Unknown Cell Type 2 |
| ADT Booster (diphtheria toxoid 2 international units + tetanus toxoid 20 international units) injection suspension, 5 x 0.5 mL vials (trade product pack) |
Unknown Cell Type 2 |
| ADT Booster injection: suspension, 0.5 mL syringe |
ADT Booster injection, 0.5 mL syringe |
| ADT Booster injection: suspension, 0.5 mL syringe |
ADT Booster injection, 0.5 mL syringe |
| ADT Booster injection: suspension, 0.5 mL syringe |
ADT Booster injection, 0.5 mL syringe |
| ADT Booster injection: suspension, 5 x 0.5 mL syringes |
ADT Booster injection, 5 x 0.5 mL syringes |
| ADT Booster injection: suspension, 5 x 0.5 mL syringes |
ADT Booster injection, 5 x 0.5 mL syringes |
| ADT Booster (diphtheria toxoid vaccine 2 international units / 0.5 mL + tetanus toxoid vaccine 20 international units / 0.5 mL) injection suspension, 0.5 mL syringe (trade product unit of use) |
ADT Booster injection, 0.5 mL syringe |
| ADT Booster injection suspension, 0.5 mL syringe |
ADT Booster injection, 0.5 mL syringe |
| ADT Booster injection suspension, 0.5 mL syringe |
ADT Booster injection, 0.5 mL syringe |
| ADT Booster (diphtheria toxoid vaccine 2 international units / 0.5 mL + tetanus toxoid vaccine 20 international units / 0.5 mL) injection suspension, 5 x 0.5 mL syringes (containered trade product pack) |
ADT Booster injection, 5 x 0.5 mL syringes |
| ADT Booster injection suspension, 5 x 0.5 mL syringes |
ADT Booster injection, 5 x 0.5 mL syringes |
| ADT Booster injection suspension, 0.5 mL syringe |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 0.5 mL syringe |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 0.5 mL syringe |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 0.5 mL vial |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 0.5 mL vial |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 0.5 mL vial |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 5 x 0.5 mL syringes |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 5 x 0.5 mL syringes |
Unknown Cell Type 2 |
| ADT Booster injection suspension, 5 x 0.5 mL vials |
Unknown Cell Type 2 |